Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Memorial Sloan Kettering Cancer Center
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07532902CT.gov A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer | — | Recruiting | — | — | — |
NCT07243938CT.gov Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET) | — | Not Yet Recruiting | — | — | — |
NCT06245356CT.gov Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer | — | Recruiting | — | — | — |
NCT06469944CT.gov Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) | — | Recruiting | — | — | — |
NCT06349044CT.gov A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies. | — | Recruiting | — | — | — |
NCT05482893CT.gov Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) | — | Recruiting | — | — | — |
NCT05218148CT.gov SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma | — | Unknown | — | — | — |
NCT05152147CT.gov A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers | — | Active Not Recruiting | — | — | — |
NCT04662710CT.gov Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Gastroesophageal Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Oxaliplatin (this asset) | Memorial Sloan Kettering Cancer Center | P3 | BB · 68 |
| Pembrolizumab | Diwakar Davar | P3 | BB |
| Nivolumab | Memorial Sloan Kettering Cancer Center | P2 | BB |
| Trastuzumab | UNICANCER | P3 | BB |
| Lenvatinib | Merck Sharp & Dohme LLC | P3 | B |
| Fluorouracilum | Memorial Sloan Kettering Cancer Center | P3 | B |
| Capecitabine | Shanghai Zhongshan Hospital | P3 | B |
| Zanidatamab | Tao Zhang | P3 | B |
| Ipilimumab | Memorial Sloan Kettering Cancer Center | P1/2 | B |
+42 more in the Gastroesophageal Adenocarcinoma cohort
Other indications for Oxaliplatin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Exocrine Pancreatic Carcinoma | — | P2/3 | BBB · 76 |
| Colon Adenocarcinoma | — | P3 | BBB · 76 |
| Colorectal Neoplasm | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Oxaliplatin in Gastroesophageal Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 13, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/oxaliplatin-gastroesophageal-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →